Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $38.00 Price Target at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective hoisted by JPMorgan Chase & Co. from $33.00 to $38.00 in a research note released on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other research analysts have also commented on SNDX. Bank of America upped their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target for the company. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 15th. Stifel Nicolaus raised their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, The Goldman Sachs Group boosted their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Trading Up 3.1 %

Syndax Pharmaceuticals stock opened at $16.09 on Thursday. Syndax Pharmaceuticals has a 1 year low of $15.00 and a 1 year high of $25.34. The firm has a market capitalization of $1.37 billion, a P/E ratio of -4.43 and a beta of 0.92. The business has a 50-day moving average of $18.60 and a 200-day moving average of $19.98.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period in the prior year, the business earned ($0.73) EPS. Research analysts anticipate that Syndax Pharmaceuticals will post -3.69 EPS for the current fiscal year.

Institutional Trading of Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SNDX. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $27,000. Values First Advisors Inc. purchased a new position in shares of Syndax Pharmaceuticals in the third quarter worth about $30,000. nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $33,000. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals during the 3rd quarter worth approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).